Connecting via Winsock to STN

Welcome to STN International! Enter x:x

L * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:29:40 ON 09 JUN 2009

=> file reg

=>
Uploading C:\Program Files\Stnexp\Queries\532074.str



chain nodes :
11 20 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 13 14 15 16 17 18
ring/chain nodes :
12
chain bonds :
3-20 9-13 10-11 11-12 12-22 20-21
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 13-14 13-18 14-15 15-16
 16-17 17-18
exact/norm bonds :
3-20 8-9 10-11 11-12
exact bonds :
5-7 6-10 7-8 9-10 9-13 12-22 20-21
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 13 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS
21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 10:30:18 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 102 TO ITERATE

100.0% PROCESSED 102 ITERATIONS 10 ANSWERS
SEARCH TIME: 00.00.01

L2 10 SEA SSS FUL L1

=> d scan

L2 10 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-3-(4-hydroxyphenyl)-, 2-phenylhydrazone
MF C21 H18 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus

=> s l2
L3 3 L2

=> d ibib abs hitstr 1-3

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1136767 CAPLUS
DOCUMENT NUMBER: 149:448215
TITLE: Preparation of 6-methoxy-4',7-dihydroxyisoflavone derivs. as antitumor agents
INVENTOR(S): Zhang, Qian; Ren, Yi; Li, Hanbin
PATENT ASSIGNEE(S): Fudan University, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 11pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101265249	A	20080917	CN 2008-10034474	20080311

PRIORITY APPLN. INFO.: CN 2008-10034474 20080311
OTHER SOURCE(S): CASREACT 149:448215; MARPAT 149:448215
GI



I

AB Title compds. [I; wherein X = OH, NH2, R, OR, NHR, OCOR, NHCOR, NHSO2R; R = (un)substituted alkyl, alkenyl, or aryl, etc.], were prepared as antitumor agents. Thus, the invention compound I (X = OMe) was prepared by condensation

of 6-methoxy-4',7-dihydroxyisoflavone with NH2OMe in 66.7% yield.

IT 1068661-28-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 6-methoxy-4',7-dihydroxyisoflavone derivs. as antitumor agents)

RN 1068661-28-8 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-, hydrazone (CA INDEX NAME)



IT 1068661-30-2P 1068661-31-3P 1068661-32-4P
1068661-33-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-methoxy-4',7-dihydroxyisoflavone derivs. as antitumor agents)

RN 1068661-30-2 CAPLUS

CN 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-, 2-phenylhydrazone (CA INDEX NAME)



RN 1068661-31-3 CAPLUS

CN Benzenesulfonic acid, 4-methyl-, 2-[7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-ylidene]hydrazide (CA INDEX NAME)



RN 1068661-32-4 CAPLUS
CN Acetic acid, 2-[7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-ylidene]hydrazide (CA INDEX NAME)



RN 1068661-33-5 CAPLUS
CN Methanesulfonic acid, 2-[7-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-ylidene]hydrazide (CA INDEX NAME)



L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:390237 CAPLUS
DOCUMENT NUMBER: 140:406680
TITLE: Preparation of aminated isoflavonoid derivatives for use in pharmaceutical compositions
INVENTOR(S): Kelly, Graham Edmund; Heaton, Andrew; Faragalla, Jane; Bremner, John

PATENT ASSIGNEE(S): Novogen Research Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004039793	A1	20040513	WO 2003-AU1446	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2504653	A1	20040513	CA 2003-2504653	20031103
AU 2003277969	A1	20040525	AU 2003-277969	20031103
EP 1556368	A1	20050727	EP 2003-769053	20031103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1708490	A	20051214	CN 2003-80102565	20031103
JP 2006513997	T	20060427	JP 2004-547289	20031103
NZ 539034	A	20080430	NZ 2003-539034	20031103
MX 2005004526	A	20050726	MX 2005-4526	20050427
NO 2005002524	A	20050526	NO 2005-2524	20050526
US 20060100238	A1	20060511	US 2005-532074	20051128
PRIORITY APPLN. INFO.:			AU 2002-952453 A	20021101
			WO 2003-AU1446 W	20031103

OTHER SOURCE(S): MARPAT 140:406680
GI



I

AB Aminated isoflavonoids, such as I [R = H, NO2, Me], were synthesized by aminating the 4-keto group of an isoflavanone. Claimed uses for these aminated isoflavanoids include treatment, prevention or amelioration of diseases associated with aberrant cell survival, aberrant cell proliferation, abnormal cellular migration, abnormal angiogenesis, abnormal estrogen/androgen balance, dysfunctional or abnormal steroid genesis,

degeneration including degenerative changes within blood vessel walls, inflammation and immunol. imbalance and for inducing apoptosis in cells expressing abnormal prosurvival phenotype, inhibiting migration of cells having an abnormal cellular migration phenotype, and inhibiting angiogenesis in tissue expressing aberrant angiogenic phenotype. Thus, isoflavonoid I (R = H) was prepared by reacting dihydrodaidzein with phenylhydrazine hydrochloride using NaOAc in MeOH. The prepared isoflavonoid derivs. were assayed for cytotoxicity against cancer cell lines, such as prostate LNCaP and DU-145 and lung carcinoma NCI-H460, for androgen inhibition, for inhibition of thromboxane synthase and COX.

IT 688358-33-0P 688358-34-1P 688358-35-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminated isoflavonoid derivs. for use in pharmaceutical compns.)

RN 688358-33-0 CAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-3-(4-hydroxyphenyl)-, 2-phenylhydrazone (CA INDEX NAME)



RN 688358-34-1 CAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-3-(4-hydroxyphenyl)-, 2-(4-nitrophenyl)hydrazone (CA INDEX NAME)



RN 688358-35-2 CAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-3-(4-hydroxyphenyl)-, 2-(4-methylphenyl)hydrazone (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1963:33236 CAPLUS
DOCUMENT NUMBER: 58:33236
ORIGINAL REFERENCE NO.: 58:5619a-c
TITLE: Studies on synthetic isoflavanones. I. Synthesis of isoflavanones by catalytic hydrogenation of isoflavones
AUTHOR(S): Inoue, Naoto
SOURCE: Sci. Repts. Tohoku Univ., First Ser. (1961), 45(No. 1), 63-7
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB PtO2 (0.1 to 0.5 g.) in 20 to 30 ml. HOAc was shaken with H under atmospheric pressure at room temperature When the absorption of H stopped a solution of 1 to 5 g. isoflavone in 60 to 130 ml. HOAc was added, the shaking repeated, and the hydrogenation stopped when 1.1 to 1.2 moles was absorbed. From the corresponding isoflavone were prepared I (R, R1, R2, R3, m.p. and m.p. 2,4-dinitrophenylhydrazone given): H, H, H, H, 77°, 209°; OH, H,H, H, 175°, 245°; OMe, H, H, H, 92°, 213°; AcO, H, H, H, 108.5°, --; H, OH, H, H, 115°, 236°; H, OMe, H, H, 108°, 219°; H, AcO, H, H, 95.5 24°, --; Oil, H, OMe, H, 197°, 254°; AcO, H, OMe, H, 150°, --; OH, H, (R23 =) CH2O2, 197°, 240°; OMe, H, (R2R3 =) CH2O2, 120°, --; AcO, H, (R2R3 =) CH2O2, 159.5°, --. Also prepared was 5,7-dimethoxyisoflavanone, m. 151°; 2,4-dinitrophenylhydrazone m. 254°.
IT 89286-03-3P, Isoflavanone, 7-hydroxy-, (2,4-dinitrophenyl)hydrazone 100733-87-7P, Isoflavanone, 7-hydroxy-4'-methoxy-, (2,4-dinitrophenyl)hydrazone
RL: PREP (Preparation)
(preparation of)
RN 89286-03-3 CAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-3-phenyl-, 2-(2,4-dinitrophenyl)hydrazone (CA INDEX NAME)



RN 100733-87-7 CAPLUS
CN 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-3-(4-methoxyphenyl)-, 2-(2,4-dinitrophenyl)hydrazone (CA INDEX NAME)



==> file marpat
Cwww.cas.org/support/stngen/stndoc/marpat.html.

=> s l2 full
FULL SEARCH INITIATED 10:32:28 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED - 2783 TO ITERATE

100.0% PROCESSED 2783 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.02

L4 7 SEA SSS FUL L1

=> d ibib abs fqhit 1-7

L4 ANSWER 1 OF 7 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 150:329425 MARPAT
TITLE: Preparation of aryl (thio)semicarbazones as inhibitors of cysteine proteases for treatment of protozoan infections such as trypanosomiasis, malaria and leishmaniasis.
INVENTOR(S): Siles, Rogelio; Zhou, Ming; Ackley, J. Freeland; Pinney, Kevin G.; Chen, Shen-En; Arispe-Angulo, Wara Milenka; Trawick, Mary Lynn
PATENT ASSIGNEE(S): Baylor University, USA
SOURCE: U.S. Pat. Appl. Publ., 28pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090076076	A1	20090319	US 2008-138806	20080613

PRIORITY APPLN. INFO.: US 2007-934512P 20070613

AB R1R2C:NN(R3)C(:X)NHR4 [R1, R2 = (substituted) Ph; R1R2 = atoms to form (substituted) 5-6 membered alicyclyl, heterocyclyl, 9-10 membered fused bialicyclyl, biheterocyclyl; R3, R4 = H, (substituted) alkyl; X = O, S], were prepared Thus, bis(3-bromophenyl) ketone (preparation given) was refluxed 15 min. in MeOH; thiosemicarbazide and HOAc were added followed by 46 h reflux to give 18% bis(3-bromophenyl) ketone thiosemicarbazone. The latter at 20 μM inhibited activated cathepsin L derived from prostate carcinoma cells.

MSTR 1



G1 = 43



G3 = NH
G12 = Ph (opt. substd. by 1 or more G14) / OH
G13 = O
Patent location: claim 1
Note: and pharmaceutically acceptable salts or tautomers
Note: or N-oxides or S-oxides
Stereochemistry: and pharmaceutically acceptable enantiomers,

stereoisomers, rotamers, diastereomers, or racemates

L4 ANSWER 2 OF 7 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 149:448215 MARPAT
TITLE: Preparation of 6-methoxy-4',7-dihydroxyisoflavone derivs. as antitumor agents
INVENTOR(S): Zhang, Qian; Ren, Yi; Li, Hanbin
PATENT ASSIGNEE(S): Fudan University, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 11pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101265249	A	20080917	CN 2008-10034474	20080311

PRIORITY APPLN. INFO.: CN 2008-10034474 20080311
OTHER SOURCE(S): CASREACT 149:448215
GI



I

AB Title compds. [I; wherein X = OH, NH2, R, OR, NHR, OCOR, NHCOR, NHSO2R; R = (un)substituted alkyl, alkenyl, or aryl, etc.], were prepared as antitumor agents. Thus, the invention compound I (X = OMe) was prepared by condensation of 6-methoxy-4',7-dihydroxyisoflavone with NH2OMe in 66.7% yield.

MSTR 1



G1 = NH2
Patent location: claim 1

L4 ANSWER 3 OF 7 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 149:252430 MARPAT

TITLE: Improvement of cognitive performance with sirtuin activators
INVENTOR(S): Sinclair, David A.; Tsai, Li-Huei; Fisher, Andre
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 60pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080194803	A1	20080814	US 2007-955680	20071213
WO 2006138418	A2	20061228	WO 2006-US23239	20060614
WO 2006138418	A3	20070913		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:		
US 2005-690306P	20050614	
US 2005-702236P	20050725	
WO 2006-US23239	20060614	

AB Provided herein are methods and compns. for enhancing the cognitive performance of a subject in need thereof. A method may include administering to a subject an agent that increases the level of protein or activity of a sirtuin, such as SIRT1. Thus, resveratrol facilitated learning and memory.

MSTR 3



G8 = heteroaryl <containing zero or more N, zero or more O, zero or more S> (opt. substd.)
G10 = 40



G11 = 42

G12 = 71

G13 = O
G14 = OH
Patent location: claim 12

L4 ANSWER 4 OF 7 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 143:483193 MARPAT
TITLE: Pharmaceutical compositions containing myricitrin or related compounds for treatment of sleeping disorders
INVENTOR(S): Chan, Hsiao Chang; Gou, Yu Lin; Rowlands, Dewi Kenneth; Chung, Yiu Wa
PATENT ASSIGNEE(S): Bright Future Pharmaceutical Laboratories Ltd., Hong Kong
SOURCE: U.S. Pat. Appl. Publ., 43 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050261167	A1	20051124	US 2005-129628	20050513
WO 2005115547	A2	20051208	WO 2005-US16783	20050513
WO 2005115547	A3	20070308		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1750808	A2	20070214	EP 2005-750345	20050513
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 101001670	A	20070718	CN 2005-80015815	20050513
JP 2007538078	T	20071227	JP 2007-527316	20050513
KR 2007020036	A	20070216	KR 2006-724012	20061116

IN 2006CN04645	A	20070629	IN 2006-CN4645	20061218
US 20090124627	A1	20090514	US 2008-340376	20081219
PRIORITY APPLN. INFO.:			US 2004-572528P	20040518
			US 2005-129628	20050513
			WO 2005-US16783	20050513

AB Provided herein is a composition that contains an effective amount of one or more compds. for treating, preventing, or ameliorating a disorder such as insomnia or another sleeping disorder and using the composition Mice were orally administered a mixture containing dihydromyricetin 75.46, myricetin 23.26, and myricitrin 1.27% 60 min prior to low dose injection of sodium pentobarbitone (12.5 mg/kg, i.p.). The mixture was able to significantly prolong pentobarbital induced-sleeping time.

MSTR 1



G1 = O
G2 = NH2 (opt. substd.)
G3 = 36

G8 = Ph (opt. substd.)
G13 = OH
Patent location: claim 1

L4 ANSWER 5 OF 7 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 140:406680 MARPAT
TITLE: Preparation of aminated isoflavonoid derivatives for use in pharmaceutical compositions
INVENTOR(S): Kelly, Graham Edmund; Heaton, Andrew; Faragalla, Jane; Bremner, John
PATENT ASSIGNEE(S): Novogen Research Pty. Ltd., Australia
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004039793	A1	20040513	WO 2003-AU1446	20031103	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2504653	A1	20040513	CA 2003-2504653	20031103	
AU 2003277969	A1	20040525	AU 2003-277969	20031103	
EP 1556368	A1	20050727	EP 2003-769053	20031103	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1708490	A	20051214	CN 2003-80102565	20031103	
JP 2006513997	T	20060427	JP 2004-547289	20031103	
NZ 539034	A	20080430	NZ 2003-539034	20031103	
MX 2005004526	A	20050726	MX 2005-4526	20050427	
NO 2005002524	A	20050526	NO 2005-2524	20050526	
US 20060100238	A1	20060511	US 2005-532074	20051128	
PRIORITY APPLN. INFO.:			AU 2002-952453	20021101	
			WO 2003-AU1446	20031103	

GI



I

AB Aminated isoflavonoids, such as I [R = H, NO2, Me], were synthesized by aminating the 4-keto group of an isoflavanone. Claimed uses for these aminated isoflavanoids include treatment, prevention or amelioration of diseases associated with aberrant cell survival, aberrant cell proliferation, abnormal cellular migration, abnormal angiogenesis, abnormal estrogen/androgen balance, dysfunctional or abnormal steroid genesis, degeneration including degenerative changes within blood vessel walls, inflammation and immunol. imbalance and for inducing apoptosis in cells expressing abnormal prosurvival phenotype, inhibiting migration of cells having an abnormal cellular migration phenotype, and inhibiting angiogenesis in tissue expressing aberrant angiogenic phenotype. Thus, isoflavonoid I (R = H) was prepared by reacting dihydrodaidzein with phenylhydrazine hydrochloride using NaOAc in MeOH. The prepared isoflavonoid derivs. were assayed for cytotoxicity against cancer cell lines, such as prostate LNCaP and DU-145 and lung carcinoma NCI-H460, for androgen inhibition, for inhibition of thromboxane synthase and COX.

MSTR 1



G7 = 7-18 2-29 15-19



G13 = 153



G21 = 46



G32 = OH
G33 = O
Patent location: claim 1
Note: or pharmaceutically acceptable salts
Note: substitution is restricted
Note: additional ring formation also claimed

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 136:401543 MARPAT
TITLE: Preparation of hydrazono(tetrahydronaphthalenyl)benzamides and insecticides and acaricides
INVENTOR(S): Mita, Takeshi; Masuzawa, Tadahide; Io, Tomoaki;

Miyake, Toshiro; Takii, Shinji; Ito, Toshiki
PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 113 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002155044	A	20020528	JP 2000-352333	20001120

PRIORITY APPLN. INFO.: JP 2000-352333 20001120
GI



I

AB The compds. I [A = CH2, CH2CH2, OCH2, S(O)pCH2, NR4CH2, etc.; Q = H, C1-12 alkyl, C1-12 haloalkyl, C3-12 cycloalkyl, etc.; W1, W2 = O, S; X, Y = H, halo, cyano, SCN, SF5, etc.; R1 = H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, etc.; R2, R3 = H, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy(C1-4 alkyl), etc.; m = 1-4; n = 1-5; p = 0-2] or their salts are prepared N-[(6-chloro-1-hydrazono)-1,2,3,4-tetrahydronaphthalen-2-yl]benzamide (0.50 g) was treated with butyryl chloride in the presence of pyridine in AcOEt at 0° to room temperature overnight to give 0.42 g N-[1-(N'-butyrylhydrazono)-6-chloro-1,2,3,4-tetrahydronaphthalen-2-yl]benzamide showing 80% insecticidal activity to Spodoptera litura.

MSTR 1



G1 = 382-1 383-3

G4—G6
382 383

G4 = O
G6 = (1-2) CH2
G43 = Ph (opt. substd.)
G44 = OH
Patent location: claim 1
Note: or salts
Note: additional ring formation also claimed

L4 ANSWER 7 OF 7 MARPAT COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 135:5616 MARPAT
TITLE: Preparation of hydrazone compounds and pesticides
INVENTOR(S): Mita, Takeshi; Ohtsu, Tadashi; Hotta, Hiroyasu; Io, Tomoaki; Ueno, Hideki; Masuzawa, Yoshihide; Miyake, Toshiro; Mimori, Norihiko; Takii, Shinji; Itoh, Toshinori
PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 409 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036381	A1	20010525	WO 2000-JP8016	20001114

W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	
JP 1999-323698	19991115
JP 1999-323699	19991115
JP 2000-298021	20000929
JP 2000-301562	20001002

GI



I

AB Hydrazone compds. such as hydrazono-1,2,3,4-tetrahydronaphthalene,

hydrazonoindoline, or hydrazochroman, resented by general formula (I) or salts thereof [wherein A = CH2, CH2CH2, OCH2, S(O)pCH2, S(O)pCH2CH2, or CH2 S(O)pCH2 (wherein p = 0-2), N-(un)substituted NHCH2, NHCH2CH2, or CH2NHCH2, (CH2)3, OCH2CH2; B = a single bond, O, S, (un)substituted NH, CO; G = -N:C(R5)NR6R7 (G-1), -N(R8)C(:W2)Q2 (G-2), -N:C(R5)W3-R9 (G-3); when B = O, S, (un)substituted NH, CO, G-1, or G-3, then Q1 = (halo)alkyl, (halo)cycloalkyl, (halo)alkenyl, (halo)alkynyl, (halo)cycloalkenyl, (un)substituted Ph, aromatic or aliphatic heterocyclyl, etc.; when B = a single bond and G = G-2, then Q1 = (halo)alkyl, (halo)cycloalkyl, (halo)alkenyl, (halo)alkynyl, (halo)cycloalkenyl, etc.; when B = a single bond or (un)substituted NH, then Q1 = H; Q2 = H, (halo)alkyl, (halo)cycloalkyl, (halo)alkenyl, (halo)alkynyl, (halo)cycloalkenyl, alkoxycarbonyl, (un)substituted benzoyl or Ph, aromatic or aliphatic heterocyclyl, etc.; W1, W2 = O, S; W3 = O, S, CH2; X = H, halo, cyano, isocyanato, NO2, N3, CHO, CO2H, (un)substituted carbamoyl, OH, SH, etc.; R1 = H, (halo)alkyl, cycloalkyl, cycloalkylalkyl, (halo)alkoxyalkyl, alkoxyalkoxyalkyl, benzyloxyalkyl, (halo)alkylthioalkyl, etc.; R2 = H, (halo)alkyl, alkoxyalkyl, alkylthioalkyl, cyanoalkyl, alkoxycarbonyl, (halo)alkenyl, etc.; m = 1-4] are prepared Novel agricultural chems., in particular, insecticides and miticides containing these compds. as the active ingredient formula I are also claimed. Thus, a solution of tert-Bu 6-chloro-1-hydrazono-1,2,3,4-tetrahydronaphthalen-2-ylcarbamate and N,N-dimethylacetamide di-Me acetal in toluene was refluxed for 4 h to give tert-Bu 6-chloro-1-[1-(dimethylamino)ethylidenehydrazono]-1,2,3,4-tetrahydronaphthalen-2-ylcarbamate (II). II at 500 ppm controlled ≥80% Spodoptera litura larvae on cabbage leaves.

MSTR 1B



G2 = O
G10 = 275



G43 = Ph (opt. substd.)
G44 = OH (opt. substd.)
Patent location: claim 1
Note: or salts

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 10:29:40 ON 09 JUN 2009)

     FILE 'REGISTRY' ENTERED AT 10:30:01 ON 09 JUN 2009
L1              STRUCTURE UPLOADED
L2           10 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 10:30:30 ON 09 JUN 2009
L3            3 S L2

     FILE 'STNGUIDE' ENTERED AT 10:31:41 ON 09 JUN 2009

     FILE 'MARPAT' ENTERED AT 10:32:24 ON 09 JUN 2009
L4            7 S L2 FULL

=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y

STN INTERNATIONAL LOGOFF AT 10:33:10 ON 09 JUN 2009
```